Guobang Pharma Ltd. (SHA:605507)

Guobang Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,226	1,460	1,909	2,094	1,974	893.01
Trading Asset Securities	1,276	1,243	617.66	465.99	824.56	1,258
Cash & Short-Term Investments	2,503	2,703	2,527	2,560	2,799	2,151
Cash Growth	13.32%	6.96%	-1.29%	-8.52%	30.09%	74.24%
Accounts Receivable	1,364	1,394	1,332	964.92	775.34	571.5
Other Receivables	10.37	43.32	67.35	17.22	21.07	45.03
Receivables	1,374	1,438	1,399	982.14	796.41	616.53
Inventory	1,788	1,776	1,363	1,369	1,409	1,309
Prepaid Expenses	-	-	-	-	-	0.7
Other Current Assets	559.78	195.95	584.67	532.31	125.15	489.48
Total Current Assets	6,224	6,113	5,874	5,443	5,129	4,567
Property, Plant & Equipment	4,368	4,289	4,344	4,330	3,284	2,622
Long-Term Investments	174.38	118.71	112.57	121.13	101.37	17.11
Goodwill	0.03	0.03	0.03	0.03	0.03	0.03
Other Intangible Assets	372.3	342.65	350.83	358.85	370.5	272.26
Long-Term Deferred Tax Assets	16.47	13.52	8.96	7.78	6.59	19.02
Long-Term Deferred Charges	6.63	6.98	7.45	8.02	9.26	2.6
Other Long-Term Assets	100.12	100.91	82.64	92.64	142.61	12.79
Total Assets	11,262	10,985	10,780	10,362	9,043	7,513

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1,563	1,196	1,704	1,715	974.35	789.71
Accrued Expenses	77.07	129.85	125.97	97.06	107.06	100.47
Short-Term Debt	365.12	512.2	181.23	488.79	664.28	168.88
Current Portion of Long-Term Debt	419.2	7.29	452.17	28.88	-	-
Current Income Taxes Payable	45.16	23.75	22.47	18.44	4.26	30.24
Current Unearned Revenue	40.99	25.35	39.93	55.85	52.79	30.68
Other Current Liabilities	34.96	26.53	32.34	45.99	59.64	33.53
Total Current Liabilities	2,545	1,921	2,558	2,450	1,862	1,154
Long-Term Debt	168.62	478.01	146.72	451.7	-	-
Long-Term Unearned Revenue	30.49	25.86	16.67	11.8	14.27	9.71
Long-Term Deferred Tax Liabilities	1.41	3.94	7.2	11.32	11.93	4.16
Total Liabilities	2,746	2,429	2,728	2,924	1,889	1,167

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	782.35	558.82	558.82	558.82	558.82	558.82
Additional Paid-In Capital	3,404	3,627	3,609	3,607	3,607	3,607
Retained Earnings	4,503	4,367	3,881	3,266	2,989	2,180
Treasury Stock	-175.13	-	-1.48	-	-	-
Total Common Equity	8,514	8,553	8,047	7,432	7,155	6,346
Minority Interest	2.7	2.43	4.72	5.15	-0.65	-0.39
Shareholders' Equity	8,517	8,556	8,052	7,437	7,155	6,346
Total Liabilities & Equity	11,262	10,985	10,780	10,362	9,043	7,513

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	952.93	997.5	780.12	969.37	664.28	168.88
Net Cash (Debt)	1,550	1,705	1,747	1,591	2,134	1,982
Net Cash Growth	23.95%	-2.37%	9.81%	-25.46%	7.66%	528.79%
Net Cash Per Share	2.01	2.20	2.23	2.04	2.73	2.77
Filing Date Shares Outstanding	770.98	782.35	781.71	777.71	782.35	782.35
Total Common Shares Outstanding	770.98	782.35	782.23	782.35	782.35	782.35
Working Capital	3,679	4,192	3,317	2,994	3,267	3,414
Book Value Per Share	11.04	10.93	10.29	9.50	9.15	8.11
Tangible Book Value	8,142	8,210	7,696	7,073	6,785	6,074
Tangible Book Value Per Share	10.56	10.49	9.84	9.04	8.67	7.76
Buildings	-	1,893	1,812	1,706	1,025	810.75
Machinery	-	4,256	3,980	3,372	2,487	1,933
Construction In Progress	-	282.88	255.26	636.65	874.85	827.46

Data Source: S&P Global Market Intelligence Last updated: Oct 23, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error